Clinician's guide to human papillomavirus immunology: knowns and unknowns (Q34982885)

5 August 2017

1 reference

title

Clinician's guide to human papillomavirus immunology: knowns and unknowns (English)

1 reference

5 August 2017

1 reference

6

Tina Tan

1 reference

5 August 2017

7

Neal Halsey

1 reference

5 August 2017

Raphael P Viscidi

3

1 reference

ORCID Public Data File 2021

Howard D Strickler

4

object named as

Howard D Strickler

1 reference

5 August 2017

Mark H Einstein

1

1 reference

5 August 2017

John T Schiller

2

1 reference

5 August 2017

Pierre Coursaget

5

1 reference

5 August 2017

David Jenkins

8

1 reference

5 August 2017

1 June 2009

1 reference

Lancet Infectious Diseases

5 August 2017

1 reference

5 August 2017

9

1 reference

5 August 2017

6

1 reference

5 August 2017

347-356

1 reference

Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

The causal relation between human papillomavirus and cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Classification of papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Human papillomaviruses target the double-stranded RNA protein kinase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

High Number of Intraepithelial CD8+Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Immune responses to human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Epigenetics of cervical cancer. An overview and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

The papillomavirus life cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Immunobiology of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Human papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells and colocalize with langerin in Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Subpopulations of Langerhans' cells in cervical neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Evaluation of Langerhans' cells in the cervical epithelium of women with cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is defective in cervical human papillomavirus-associated (pre)neoplastic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Imiquimod: mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Genetic variants in TAP are associated with high-grade cervical neoplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Risk of Cancer in Relatives of Prostate Cancer Probands

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Risk factors for rapid-onset cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Activation of latent papillomavirus genomes by chronic mechanical irritation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Human Papillomavirus Type 11 Transcripts Are Present at Low Abundance in Latently Infected Respiratory Tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

A long way: history of the prophylactic papillomavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Natural history of cervicovaginal papillomavirus infection in young women.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970108-2

7 January 2021

10.1016/S1473-3099(09)70108-2

Identifiers

DOI

1 reference

5 August 2017

1 reference